Pharmaceutical development and clinical effectiveness of a novel gel technology for transdermal drug delivery

Bibliography

• BETAGERI G, PRABHU S: Semisolid preparations. In: Encyclopedia of Pharmaceutical Technology (Volume 3, 2nd Edition). J S JC Boylan (Eds), Marcel Dekker, Inc., New York, NY, USA (2002):2436–2457.
   Google Scholar
• ••A good overview of semisolid dosageforms.
   Google Scholar
• RESCH K, SCHILLING C, BORCHERT BD, KLATZKO M, UDEN D: Topical anaesthesia for paediatric lacerations: a randomized trial of lidocaine-epinephrine-tetracaine solution versus gel. Ann. Emerg. Med. (1998) 32 (6) : 693–697.
   Google Scholar
• ECCLESTON GM: Emulsions and microemulsions. In: Encyclopedia of Pharmaceutical Technology (Volume 2, 2nd Edition). J S JC Boylan (Eds), Marcel Dekker, Inc., New York, NY, USA (2002):1066–1085.
   Google Scholar
• OWEN SC: Alcohol monograph. In: Handbook of Pharmaceutical Excipients (4th Edition). RC R PJ S PJ Weller (Eds), The Pharmaceutical Press and the American Pharmaceutical Association, Chicago, IL, USA (2003):13–15.
   Google Scholar
• TAKRURI H, ANGER CB: Preservation of dispersed systems. In: Pharmaceutical Dosage Forms: Disperse Systems (Volume 2). HA L MM R GS Banker (Eds), Marcel Dekker, Inc., New York, NY, USA (1989):73–114.
   Google Scholar
• WELLER PJ: Propylene glycol monograph. In: Handbook of Pharmaceutical Excipients (4th Edition). RC R PJ S PJ Weller (Eds), The Pharmaceutical Press and the American Pharmaceutical Association, Chicago, IL, USA (2003):521–523.
   Google Scholar
• DAVIS AF, GRAFT J: Supersaturated solutions as topical drug delivery systems. In: Pharmaceutical Skin Penetration Enhancement (Volume 59). KA W J Hadgraft (Eds), Marcel Dekker, Inc., New York, NY, USA (1993):243–267.
   Google Scholar
• MURAHATA RI, TOTON-QUINN R, FINKEY MB: Effect of pH on the production of irritation in a chamber irritation test. J. Am. Acad. Dermatol (1988) 18(1 Pt 1):62–66.
   Google Scholar
• BUCHER K, BUCHER KE, WALZ D: Irritant actions of unphysiological pH values. A controlled procedure to test for topical irritancy. Agents Actions. (1979) 9(1):124–132.].
   Google Scholar
• ROY SD: Preformulation aspects of transdermal drug delivery systems. In: Transdermal and Topical Drug Delivery Systems. TK G WR P SI Yum (Eds), Interpharm Press, Inc., Buffalo Grove, NY, USA (1997):139–166.
   Google Scholar
• ••A good overview of transdermal andtopical dosage forms formulation.
   Google Scholar
• WELIN-BERGER K, NEELISSEN JA, BERGENSTAHL B: The effect of rheological behaviour of a topical anaesthetic formulation on the release and permeation rates of the active compound. Eur. Pharm. Sci. (2001) 13(3):309–318.
   Google Scholar
• BAGATELL CJ, BREMNER WJ: Androgens in men - uses and abuses. N. Engl. J. Med. (1996) 334(11):707–714.
   Google Scholar
• WINTERS SJ: Current status of testosterone replacement therapy in men. Arch. Fam. Med. (1999) 8(3):257–263.
   Google Scholar
• AACE Hypogonadism Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients-2002 update. Endocr. Pract. (2002) 8(6):439–456.
   Google Scholar
• •The official reference for hypogonadism.
   Google Scholar
• VERMEULEN A: Androgen replacement therapy in the aging male - a criticalevaluation. J. Clin. Endocrinol Metab. (2001) 86(6):2380–2390.
   Google Scholar
• •A thorough critical review.
   Google Scholar
• CUNNINGHAM GR, CORDERO E, THORNBY JI: Testosterone replacement with transdermal therapeutic systems. Physiological serum testosterone and elevated dihydrotestosterone levels. JAMA (1989) 261(17):2525–2530.
   Google Scholar
• MEIKLE AW, MAZER NA, MOELLMER JF et al: Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J. Clin. Endocrinol Metab. (1992) 74(3):623–628.
   Google Scholar
• PARKER S, ARMITAGE M: Experience with transdermal testosterone replacement therapy for hypogonadal men. Clin. Endocrinol (1999) 50(1):57–62.
   Google Scholar
• SWERDLOFF RS, WANG C, CUNNINGHAM G et al.: Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. Clin. Endocrinol Metab. (2000) 85(12):4500–4510.
   Google Scholar
• WANG C, CUNNINGHAM G, DOBS A et al.: Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. I. Clin. Endocrinol Metab. (2004) 89(5):2085–2098.
   Google Scholar
• SWERDLOFF RS, WANG C: Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel. Aging Male (2003) 6(3):207–211.
   Google Scholar
• MARBURY T, HAMILL E, BACHAND R, SEBREE T, SMITH T: Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim, compared to AndroGel. Biopharm. Drug. Dispos. (2003) 24(3):115–120.
   Google Scholar
• MCNICHOLAS TA, DEAN JD, MULDER H, CARNEGIE C, JONES NA: A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. RIU Int. (2003) 91(1):60–74.
   Google Scholar
• MEIKLE AW, MATTHIAS D, HOFFMAN AR: Transdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men. RIU Int. (2004) 93(6):789–795.
   Google Scholar
• ROSSOUW JE, ANDERSON GL, PRENTICE RL et al.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women. "AMA (2002) 288(3):321–333.
   Google Scholar
• CORTELLARO M, NENCIONI T, BOSCHETTI C et al: Cyclic hormonal replacement therapy after the menopause: transdermal versus oral treatment. Eur. Clin. Pharmacol (1991) 41(6):555–559.
   Google Scholar
• CROOK D: The metabolic consequences of treating postmenopausal women with non-oral hormone replacement therapy. BE Obstet. Cynecol. (1997) 104\(Suppl. 16):4–13.
   Google Scholar
• ERENUS M, KARAKOC B, GURLER A: Comparison of effects of continuous combined transdermal with oral estrogen and oral progestogen replacement therapies on serum lipoproteins and compliance. Climacteric (2001) 4(3):228–234.
   Google Scholar
• NOTELOVITZ M, CASSEL D, HILLE D et al.: Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause. Am. J. Obstet. Cynecol (2000) 182(1 Pt 1):7–12.
   Google Scholar
• RUBINACCI A, PERUZZI E, MODENA AB et al: Effect of low-dose transdermal E2, -/NETA on the reduction of postmenopausal bone loss in women. Menopause (2003) 10(3):241–249.
   Google Scholar
• ARCHER DF, FURST K, TIPPING D, DAIN MP, VANDEPOL C: A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group. Obstet. Cynecol. (1999) 94(4):498–503.
   Google Scholar
• BRYNHILDSEN J, HAMMAR M: Low dose transdermal estradiolinorethisterone acetate treatment over 2 years does not cause endometrial proliferation in postmenopausal women. Menopause (2002) 9(2):137–144.
   Google Scholar
• HIRVONEN E, CACCIATORE B, WAHLSTROM T, RITA H, WILEN-ROSENQVIST G: Effects of transdermal oestrogen therapy in postmenopausal women: a comparative study of an oestradiol gel and an oestradiol delivering patch. BE J. Obstet. Cyriaecol. (1997) 104\(Suppl. 16):26–31.
   Google Scholar
• TRAVASSOS DE ALVES S, GOMES MA, CLAPAUCH R: Comparison of gel and patch estradiol replacement in Brazil, a tropical country. Maturitas (2000) 36(1):69–74.
   Google Scholar
• SCOTT RT, ROSS B, ANDERSON C, ARCHER DF: Pharmacokinetics of percutaneous estradiol: a crossover study using a gel and a transdermal system in comparison with oral micronized estradiol. Obstet. Cynecol. (1991) 77(5):758–764.
   Google Scholar
• JARVINEN A, NYKANEN S, PAASINIEMI L: Absorption and bioavailability of oestradiol from a gel, a patch and a tablet. Maturitas (1999) 32(2):103–113.
   Google Scholar
• ABRAMS P, CARDOZO L, FALL M et al.:The standardisation of terminology in lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Urology (2003) 61(1):37–40.
   Google Scholar
• MILSOM I, ABRAMS P, CARDOZO L, ROBERTS RG, THUROFF J, WEIN J: How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJUInt. (2001) 87(9):760–766.
   Google Scholar
• VAN ROOYEN JB, CUNDIFF GW et al.: Prevalence and burden of overactive bladder in the United States. World Um]. (2003) 20(6):327–336.
   Google Scholar
• WALDECK K, LARSSON B, ANDERSSON KE: Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. I. Um]. (1997) 157(3):1093–1097.
   Google Scholar
• APPELL RA, CHANCELLOR MB, ZOBRIST RH, THOMAS H, SANDERS SW: Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin. Proc. (2003) 78(6):696–702.
   Google Scholar
• DMOCHOWSKI RR, SAND PK, ZINNER NR, GITTELMAN MC, DAVILA GW, SANDERS SW: Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology (2003) 62(2):237–242.
   Google Scholar
• DAVILA GW, DAUGHERTY CA, SANDERS SW: A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. I. Urol. (2001) 166(1):140–145.
   Google Scholar
• ZOBRIST RH, QUAN D, THOMAS HM, STANWORTH S, SANDERS SW: Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery system. Pharm. Res. (2003) 20(1):103–109.
   Google Scholar
• DMOCHOWSKI RR, DAVILA GW, ZINNER NR: Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. Urol. (2002) 168(2):580–586.
   Google Scholar
• GREENBLATT DJ, WRIGHT CE: Clinical pharmacokinetics of alprazolam. Therapeutic implications. Clin. Pharmacokinet. (1993) 24(6):453–471.
   Google Scholar
• PAI HV, UPADHYA SC, CHINTA SJ, HEGDE SN, RAVINDRANATH V: Differential metabolism of alprazolam by liver and brain cytochrome (P4503A) to pharmacologically active metabolite. Pharmacogenernics J. (2002) 2(4):243–258.
   Google Scholar
• MARTIN WR, SLOAN RV, WALA E: Precipitated abstinence in orally dosed benzodiazepine-dependent dogs. Pharmacol Exp. Ther. (1990) 255(2):744–755.
   Google Scholar
• YASUI N, OTANI K, KANEKO S et al: A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Clin. Pharmacy]. Ther. (1996) 59(5):514–519.
   Google Scholar
• WANG C, SWERDLOFF RS, IRANMANESH A et al: Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. I Clin. Endocrine]. Metab. (2000) 85(8):2839–2853.
   Google Scholar
• GUY RH, HADGRAFT J: Selection of drug candidates for transdermal drug delivery. In: Transdermal drug delivery (Volume 35). J H RH Guy (Eds), Marcel Dekker, Inc., New York, NY, USA (1989):59–81.
   Google Scholar
• ••This is essential reading for understandingthe requirements for transdermal drugs.
   Google Scholar
• RVINEN A, GRANANDER M, NYKANEN S, LAINE T, GEURTS P, VITAANEN A: Steady-state pharmacokinetics of oestradiol gel in post menopausal women: effects of application area and washing. BE I Obstet. Cynaecol. (1997) 104(s16):14–18.
   Google Scholar
• ROLF C, KNIE U, LEMMNITZ G, NIESCHLAG E: Interpersonal testosterone transfer after application of a newly developed testosterone gel preparation. Endocrine]. (2002) 56(5):637–641.
   Google Scholar